Close Menu

In Science Signaling this week, researchers in the UK say amplification of oncogenes KRAS or BRAF underpins an acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. The researchers modeled acquired resistance to the MEK 1/2 inhibitor selumetinib in colorectal cancer cells with BRAF or KRAS mutations. Genomic sequencing showed no acquired mutations in MEK1 or MEK2, selumetinib's primary targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.